Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer

NCT06321484 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06321484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
October 9, 2024
Completion date
October 31, 2031
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell ovarian carcinoma, endometroid ovarian carcinoma, ovarian cancer, ovarian carcinoma, ovarian carcinoma, recurrent, platinum-resistant ovarian cancer, recurrent ovary cancer